Drug Profile
Seliforant - Sensorion
Alternative Names: SENS-111; UR-63325Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Palau Pharma
- Developer Palau Pharma; Sensorion
- Class Antiallergics; Antiasthmatics; Antihistamines; Azetidines; Pyrimidines; Small molecules; Vestibular disorder therapies
- Mechanism of Action Histamine H4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Vertigo
- No development reported Asthma; Seasonal allergic rhinitis; Tinnitus
Most Recent Events
- 28 May 2021 No recent reports of development identified for phase-I development in Vertigo in France (PO, Capsule)
- 20 May 2020 Sensorion completes a phase-II clinical trials in Vertigo in Germany, Hungary, Poland, Czech Republic (PO) (NCT03110458) (EudraCT2016-003927-45)
- 23 Oct 2019 Sensorion terminates phase II trial in vertigo in Spain (EudraCT2016-003927-45)